Cargando…

The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma

BACKGROUND: Lenvatinib is appropriate for reducing the production of nitric oxide (NO) and facilitating as block angiogenesis. However, to our knowledge, there are no data that support the correlation between NO and clinical response in patients who received lenvatinib therapy for HCC. Therefore, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawamura, Atsushi, Uojima, Haruki, Chuma, Makoto, Shao, Xue, Hidaka, Hisashi, Nakazawa, Takahide, Take, Akira, Sakaguchi, Yoshihiko, Numata, Kazushi, Kako, Makoto, Nozaki, Akito, Azuma, Shintaro, Horio, Kazue, Kusano, Chika, Atsuda, Koichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396897/ https://www.ncbi.nlm.nih.gov/pubmed/35999529 http://dx.doi.org/10.1186/s12885-022-10002-x

Ejemplares similares

Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib
por: Azuma, Shintaro, et al.
Publicado: (2020)

Author Correction: Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib
por: Azuma, Shintaro, et al.
Publicado: (2021)

A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma
por: Kobayashi, Satoshi, et al.
Publicado: (2022)

Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma
por: Chuma, Makoto, et al.
Publicado: (2020)

Safety and Efﬁcacy of Lenvatinib Treatment in Child–Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis
por: Ogushi, Katsuaki, et al.
Publicado: (2020)

Comparative study between sorafenib and lenvatinib as the first‐line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real‐world setting
por: Fukushima, Taito, et al.
Publicado: (2021)

Lenvatinib for large hepatocellular carcinomas with portal trunk invasion: Two case reports
por: Komiyama, Satoshi, et al.
Publicado: (2020)

Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
por: Fukushima, Taito, et al.
Publicado: (2023)

Combination Therapy With Lenvatinib and Radiofrequency Ablation for Patients With Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh Class A Liver function: A Pilot Study
por: Wang, Feiqian, et al.
Publicado: (2022)

The Risk of Cirrhosis and Its Complications Based on PNPLA3 rs738409 G Allele Frequency
por: Shao, Xue, et al.
Publicado: (2022)

EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells
por: He, Xiaoping, et al.
Publicado: (2022)

Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression
por: Kondo, Masaaki, et al.
Publicado: (2017)

Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment
por: Chuma, Makoto, et al.
Publicado: (2022)

Real impact of tumor marker AFP and PIVKA-II in detecting very small hepatocellular carcinoma (≤ 2 cm, Barcelona stage 0) - assessment with large number of cases
por: Tarao, Kazuo, et al.
Publicado: (2020)

Usefulness of autotaxin for the complications of liver cirrhosis
por: Shao, Xue, et al.
Publicado: (2020)

Comparison of vascularity observed using contrast-enhanced 3D ultrasonography and pathological changes in patients with hepatocellular carcinoma after sorafenib treatment
por: Fukuda, Hiroyuki, et al.
Publicado: (2018)

Comparison of unenhanced magnetic resonance imaging and ultrasound in detecting very small hepatocellular carcinoma
por: Tarao, Kazuo, et al.
Publicado: (2021)

Cartilage-hair Hypoplasia Complicated with Liver Cirrhosis Due to Chronic Intrahepatic Cholestasis
por: Kogami, Taro, et al.
Publicado: (2021)

Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection: A prospective observational study
por: Nozaki, Akito, et al.
Publicado: (2021)

Hepatocellular carcinoma effective stereotactic body radiotherapy using Gold Anchor and the Synchrony system: Two case reports and review of literature
por: Masuda, Sakue, et al.
Publicado: (2022)

Splenectomy for Torsion of a Wandering Spleen in a Patient with Myeloproliferative Disease
por: Imawari, Kana, et al.
Publicado: (2021)

A suspected case of Clostridium perfringens sepsis with intravascular hemolysis after transhepatic arterial chemoembolization: a case report
por: Uojima, Haruki, et al.
Publicado: (2019)

Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study
por: Uojima, Haruki, et al.
Publicado: (2017)

Platypnea-orthodeoxia Syndrome Induced by an Infected Giant Hepatic Cyst
por: Hyun Sung, Ji, et al.
Publicado: (2017)

Usefulness of 3D slicer for the planning and monitoring of hepatocellular carcinoma treatment using FUS
por: Doba, Nobutaka, et al.
Publicado: (2015)

Effectiveness of entecavir in preventing hepatocellular carcinoma development is genotype-dependent in hepatitis B virus-associated liver cirrhosis
por: Tarao, Kazuo, et al.
Publicado: (2021)

Diagnostic Value of Imaging Methods in the Histological Four Grading of Hepatocellular Carcinoma
por: Wang, Feiqian, et al.
Publicado: (2020)

Added Value of Ultrasound-Based Multimodal Imaging to Diagnose Hepatic Sclerosed Hemangioma before Biopsy and Resection
por: Wang, Feiqian, et al.
Publicado: (2022)

Secondary Minimal Change Disease Due to Pancreatic Cancer Improved by Chemotherapy
por: Masuda, Sakue, et al.
Publicado: (2020)

Therapeutic effects of regorafenib after sorafenib monotherapy with advanced hepatocellular carcinoma including Child–Pugh classification B: A retrospective observational study
por: Komiyama, Satoshi, et al.
Publicado: (2020)

Relationship between response to lusutrombopag and splenic volume
por: Uojima, Haruki, et al.
Publicado: (2018)

Late Relapse after a Sustained Virologic Response at 24 Weeks after Treatment with Daclatasvir and Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b Infection with Liver Cirrhosis
por: Uojima, Haruki, et al.
Publicado: (2017)

Peliosis hepatis disseminated rapidly throughout the liver in a patient with prostate cancer: a case report
por: Hidaka, Hisashi, et al.
Publicado: (2015)

Respiratory motion tracking system of hepatocellular carcinoma treatment using FUS
por: Fukuda, Hiroyuki, et al.
Publicado: (2015)

Undifferentiated Embryonal Sarcoma of the Liver Identified after the Initial Diagnosis of a Hepatic Cyst
por: Manabe, Yusaku, et al.
Publicado: (2020)

Direct oral anticoagulants increase bleeding risk after endoscopic sphincterotomy: a retrospective study
por: Masuda, Sakue, et al.
Publicado: (2021)

Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study
por: Matsuyama, Chihiro, et al.
Publicado: (2023)

Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma
por: Takada, Juichi, et al.
Publicado: (2015)

Optimal use of lenvatinib in the treatment of advanced thyroid cancer
por: Takahashi, Shunji, et al.
Publicado: (2017)

Safety and efficacy study: Short-term application of radiofrequency ablation and stereotactic body radiotherapy for Barcelona Clinical Liver Cancer stage 0–B1 hepatocellular carcinoma
por: Wang, Feiqian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2noj01sr7n3r5krskkem5irfpq